Loading clinical trials...
Loading clinical trials...
A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED NIRMATRELVIR/RITONAVIR IN PREGNANT WOMEN WITH MILD-TO-MODERATE COVID-19
Conditions
Interventions
nirmatrelvir
ritonavir
Locations
13
United States
University of Alabama at Birmingham/Center for Women's Reproductive Health
Birmingham, Alabama, United States
Beautiful Minds Clinical Research Center
Cutler Bay, Florida, United States
Omega Research Debary
DeBary, Florida, United States
Omega Research Orlando
Orlando, Florida, United States
Santos Research Center
Tampa, Florida, United States
Clinical Research Prime
Idaho Falls, Idaho, United States
Start Date
June 22, 2022
Primary Completion Date
March 26, 2025
Completion Date
May 12, 2025
Last Updated
July 29, 2025
NCT04565665
NCT04978571
NCT06082518
NCT07221162
NCT06631287
NCT06679140
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions